2007

•Menendez C, Schellenberg D, Macete E, et al. Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. Malar J 2007, 6:132

•Grobusch M, Lell B, Schwarz N, et al. Intermittent preventive treatment against malaria in infants in Gabon: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2007, 196:1595-602.

•Alexander N, Sutherland C, Roper C, et al. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J 2007, 6:9

•Kobbe R, Kreuzberg C, Adjei S, et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 2007, 45:16-25.

•Mockenhaupt F, Reither K, Zanger P, et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, and placebo-controlled trial in northern Ghana. Antimicrobial Agents & Chemotherapy 2007, 51:3273-81.

•Kobbe R, Adjei S, Kreuzberg C, et al. Malaria incidence and efficacy of intermittent preventive treatment in infants (IPTi). Malar J 2007, 6:163

•Schreiber N, Kobbe R, Adjei S, et al. Immune responses after single-dose sulphadoxine-pyrimethamine indicate underestimation of protective efficacy of intermittent preventive treatment in infants. Trop Med Int Health 2007, 12: 1157-63.

•Chandramohan D, Webster J, Carneiro I, et al. Is the expanded programme on immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in west Africa? Trop Med Int Health 2007, 12:743-50.

•Greenwood B. Intermittent preventive antimalarial treatment in infants. Clin Infect Dis 2007, 45:26-7.

2006

•Macete E, Aide P, Aponte JJ, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican Infants: a randomized, placebo-controlled trial. J Infect Dis 2006, 194:276-85.

•Pool R, Munguambe K, Macete E, et al. Community response to intermittent preventive treatment delivered to infants (IPTi) through the EPI system in Manhiça, Mozambique. Trop Med Int Health 2006, 11:1670-8.

•Gosling DR, Schellenberg MD, Chandramohan D. Single-dose sulfadoxine-pyrimethamine in intermittent preventive treatment of malaria. J Infect Dis 2006, 193:1609-10.

2005

•Chandramohan D, Owusu-Agyei S, Carneiro I, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 2005, 331:727-33.

•Schellenberg D, Menendez C, Aponte J, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005, 365:1481-3.

•Marks F, von Kalckreuth V, Kobbe R, et al. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J Infect Dis 2005, 192:1962-5.

2003

•Massaga JJ, Kitua AY, Lemnge MM, et al. Effect of intermittent treatment with amodiaquine on anaemia and malaria fever in infants in Tanzanian: a randomised placebo-controlled trial. Lancet 2003, 361:1853-60.

2001

•Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001, 357:1471-7. 

IPTi Consortium updates

•Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health 2005, 10:815-7.

•Schellenberg D, Cissé B, Menendez C. The IPTi Consortium: research for policy and action. Trends Parasitology 2006, 22:296-300.

•Grobusch MP, Egan A, Gosling RD, Newman, RD. Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 2007, 20:613-20

IPT / IPTi articles & reviews

•Chemoprophylaxis and intermittent treatment for preventing malaria in children. Review. 2008, The Cochrane Collaboration

•Munday S. Review of intermittent preventive treatment for malaria in infants and children. J Paediatr Child Health 2007, 43:424-8.

•ter Kuile OF, Ejik van AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. JAMA 2007 297:2603-16.

•ter Kuile OF, Steketee WR. Intermittent preventive treatment in infants- adjusting expectations and seeing opportunities. J infect Dis 2006, 194:269-72.

•O'Meara WP, Smith LD, McKenzie FE. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Medicine 2006, 3(5):e141.

•White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005, 2:28-33.

•O'Meara WP, Breman JG, McKenzie FE. The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J 2005, 4:33-43.

•Bates I. Presumptive malaria treatment in immunisation programmes. Lancet 2005, 365:1443-4.

•Breman GJ, O'Meara WP. Intermittent preventive treatment for malaria in infants: moving forward, cautiously. J Infect Dis 2005, 192:1869-71.

•O'Meara WP, Breman JG, McKenzie FE. Intermittent preventive malaria treatment in Tanzanian infants. Lancet 2005, 366.

•Rosen JB, Breman JG. Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations. Lancet 2004, 363:1386-8.

•Krüger C. Malaria intermittent preventive treatment and EPI coverage. Lancet 2004, 363:200-1.

IPT in anaemic children

•Desai MR, Mei JV, Kariuki SK, et al. Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anemia in western Kenya. J Infect Dis 2003, 187:658-66.

•Verhoef H, West CE, Nzyuko SM, et al. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet 2002, 360:908-14.

Seasonal IPT in children

•Dicko A, Sagara I, Sissoko MS, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 2008, Jul 8;7(1):123

•Clarke S, Jukes M, Njagi J.Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 9633: 127-38

•Sokhna C, Cissé B, Bà EH, et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One 2008: e1471.

•Cissé B, Sokhna C, Boulanger D, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006, 367:659-67.

Additional publications mentioned in the website

•Greenwood BM, David PH, Otoo-Forbes LN, et al. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg. 1995, 89:629-33.

•Menendez C, Kahigwa E, Hirt R, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 1997, 350:844-50.

•Aponte JJ, Menendez C, Schellenberg D, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 2007, Jul 31;4(7):e242. Erratum in: PLoS Med. 2007 Dec;4(12):e359.

•Geerligs PD, Brabin BJ, Eggelte TA. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ. 2003, 81(3):205-16. Epub 2003 May 16. Review.

•Laing AB. The impact of malaria chemoprophylaxis in Africa with special reference to Madagascar, Cameroon, and Senegal. Bull World Health Organ. 1984;62 Suppl:41-8.

•Otoo LN, Snow RW, Menon A, et al. Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis. Trans R Soc Trop Med Hyg. 1988, 82:59-65.

•Hogh B, Thompson R, Lobo V, et al. The influence of Maloprim chemoprophylaxis on cellular and humoral immune responses to Plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique. Acta Trop. 1994, 57:265-77.

•Armstrong Schellenberg JR, Mrisho M, Manzi F, et al. Health and survival of young children in southern Tanzania. BMC Public Health 2008, 8:194.

•Shirima K, Mukasa O, Armstrong Schellenberg JA, et al. The use of Personal Digital Assistants for data entry at the point of collection in a large household survey in southern Tanzania. Emerging Themes in Epidemiology 2007, 4(5) doi:10.1186/1742-7622-4-5.

•Smith T, Killeen GF, Maire N, et al. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview. Am J Trop Med Hyg 2006, 72(Suppl 2):1-10.

•Smith T, Maire N, Ross A, et al. Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology 2008, 135:1507-16. Epub 2008 Aug 11.